Optimi Health ships psilocybin capsules to Australia in third export
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
June 29, 2026 9:00 AM EDTOptimis 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.
The export marks Optimis third commercial shipment since launching the 5mg psilocybin capsules in September 2025.
VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the Company or... More
